Understanding the potential benefits of VUMERITY
In clinical trials, a medication called dimethyl fumarate was tested in people with relapsing-remitting MS. Once it’s processed in the body, VUMERITY® (diroximel fumarate) takes the same active form as dimethyl fumarate. The information from the clinical trials is dimethyl fumarate data.
Two
separate studies
Each study
lasted two years
Over 1,500
people
|
|
VUMERITY is a pill that helps in three ways
Cuts relapses
Relapses (also called flare-ups or exacerbations) can be disruptive. Reducing the risk of relapses should be one of the goals of treatment.
Although no relapsing MS medication completely gets rid of relapses, dimethyl fumarate has been shown to reduce relapses compared with placebo.
Dimethyl fumarate cut the risk of relapses
27% of people taking dimethyl fumarate had a relapse, compared with 46% taking placebo.
Dimethyl fumarate cut the number of relapses
Dimethyl fumarate cut the number of relapses by 53% compared with placebo (dimethyl fumarate 0.172, placebo 0.364).
Dimethyl fumarate cut the risk of relapses
29% of people taking dimethyl fumarate had a relapse, compared with 41% taking placebo.
Dimethyl fumarate cut the number of relapses
Dimethyl fumarate cut the number of relapses by 44% compared with placebo (dimethyl fumarate 0.224, placebo 0.401).
May delay
disability progression
disability progression
When you have relapsing MS, you know how important it is to stay as active and mobile as you possibly can.
Dimethyl fumarate was shown to delay the progression of disability, which is an important goal of treatment.
Disability progression was less likely
38% less likely
16% of people taking dimethyl fumarate experienced disability progression, compared with 27% taking placebo.
21% less likely
13% of people taking dimethyl fumarate experienced disability progression, compared with 17% taking placebo.
There was no statistically significant effect on disability progression in Study 2.
Slows the development of
brain lesions
brain lesions
The link between brain lesions and the progression of relapsing MS has not been confirmed. However, lesions can happen without you feeling them, which may be a sign that the disease is active. Brain lesions revealed on a magnetic resonance imaging (MRI) scan may help your healthcare provider determine how well your treatment is working. Talking to your healthcare provider about the results of your MRI could help with the management of your relapsing MS.
How dimethyl fumarate may help
To understand the impact of dimethyl fumarate on brain lesions, researchers looked at lesions using three different MRI techniques to determine the age and stage of the lesions. Based on all three measures, people taking dimethyl fumarate had fewer lesions compared with those taking placebo.
|
|
|
|
|
|
